Jonathan Moshinsky is a healthcare technology executive with over 15 years of international leadership experience spanning life sciences software, clinical research, and strategy consulting, including roles at high-growth startups and global corporations.
He co-founded Stitch in 2021 to address the industry-wide challenge of patient dropout in clinical trials. The London-based company’s platform improves participant retention by enhancing the trial experience for patients through user-friendly digital tools and real-time feedback. Under Moshinsky’s leadership, Stitch has secured a multi-million-pound seed investment and partnered with leading research organisations such as Cancer Research UK to advance its patient-focused platform.
Prior to founding Stitch, Jonathan Moshinsky served as Chief Strategy Officer at uMotif, a digital health company focused on patient-reported data capture for clinical research. In that capacity, Moshinsky led strategic initiatives that helped global pharmaceutical sponsors adopt more patient-centric clinical trial technologies and contributed to uMotif’s growth as a platform for patient engagement.
Earlier in his career, he held senior roles in the Commercial Strategy team at Veeva Systems, a global provider of cloud software for the life sciences sector, where he worked with pharmaceutical and biotech clients to implement innovative digital solutions. He also spent several years at IBM, rising to the position of Managing Consultant and advising major global healthcare and pharmaceutical clients on business strategy and technology implementation.
Prior to IBM, Moshinsky began his career as a medical writer at Medaxial (now part of Covance), producing scientific communications for life sciences clients. He holds a Bachelor of Science degree in Biology and History and Philosophy of Science from the University of Leeds.
Throughout his career, Moshinsky has been dedicated to leveraging technology and data to improve patient outcomes and the efficiency of clinical research, ultimately helping accelerate the development of new therapies. He has also spoken at industry conferences on patient-centric clinical trial innovation.
Links
